Benitec Biopharma Inc. - 8-K Filing

Benitec Biopharma receives formal feedback from FDA following Type C meeting for BB-301 pivotal study (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $BNTC

Read the full article at SEC EDGAR

More Regulatory news